Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03727230
Other study ID # DEL
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2016
Est. completion date November 30, 2021

Study information

Verified date March 2022
Source Guangzhou Blood Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Red blood cells (RBCs) from Asian-type DEL blood group express very weak RhD antigen and are falsely typed as RhD-negative blood group in routine RhD testing. Until now, Asian-type DEL (D-eluate) patients still be treated as rare RhD-negative patients in the clinic. Previous study from the Asian-type DEL pregnant women with RhD+ fetus showed no occurrence of alloanti-D immunization. This result, however, does not directly be applied for Asian-type DEL patients receiving RhD+ blood transfusions, as lacking of direct evidence regarding the safety and underlying mechanism. In this study, the patients with Asian-type DEL were identified and received RhD+ blood transfusion, then evaluations of any adverse reactions, especially the active follow-up alloantibody test, were prospectively conducted.


Description:

Red blood cells (RBCs) from Asian-type DEL individuals express very weak RhD antigen and are falsely typed as RhD-negative in routine RhD testing. Recent studies have shown that 9-30% of individuals with a serologically apparent RhD-negative phenotype in East and Southeast Asian populations, including Chinese, Korean, Japanese, Thai and Myanmar, actually are not truly RhD-negative but exhibit the DEL (D-eluate) phenotype, which represents almost 1.7 million Asian-type DEL individuals in China, 250,000 in Korea, Japan, Thailand, and Myanmar as well as at least 90,000 in the US among Asian immigrants. Nowadays, Asian-type DEL patients are conventionally transfused with RhD-negative RBC, which are difficult to organize because of the undersupply of the rare RhD-negative blood in these Asian countries, due to low frequency distribution (0.3-0.4%). However, our previous study demonstrated that Asian-type DEL pregnant women with RhD+ fetus did not develop alloanti-D during the pregnancy. Latter, this phenomenon was confirmed by different medical centers in China. Accordingly, Asian-type DEL patients may also not be able to produce alloanti-D after transfusion with RhD+ RBC and consequently the use of RhD-negative RBCs for the transfusion management of Asian-type patients may be superfluous. However, this hypothesis needs to be carefully proved. In this study, we were able to verify this assumption. Blood samples from 2,011 Chinese patients with a primary RhD-negative phenotype from the hospitals in Guangzhou of China were typed for Asian-type DEL blood group in the Guangzhou Blood Center. DEL phenotyping was performed by the serological adsorption/elution antibody testing and genotyping for the Asian-type DEL specific allele (RHD*1227A) detection was conducted using a well validated high-resolution melting (HRM) approach. Then, transfusions of RhD+ RBC were performed in a cohort of Asian-type DEL patients. After RhD+ blood transfusion, evaluations of any adverse reactions, especially the active follow-up alloantibody test, were conducted to evaluate the alloanti-D immunization. Besides, effectiveness of transfusion (Hb changes) was also recorded.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date November 30, 2021
Est. primary completion date October 9, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion criteria for eligible participants were as follows: (1) Asian-type DEL blood group; (2) male patients, or female patients = 49 years of age, or female with severe illness and no plan for further pregnancy; (3) needing blood transfusion in line with guidelines for internal medicine or surgery; and (4) signed voluntary informed consent for blood transfusion treatment before the trial. The exclusion criteria were: (1) adverse reaction in a previous transfusion; (2) allergies to blood products or immunodeficiency diseases; (3) needing massive blood transfusion for acute blood loss; (4) positive pregnancy test results; (5) conscious dysfunction or severe mental illness; and (6) unsuitability for the study, as estimated by the principal investigators.

Study Design


Intervention

Other:
Blood transfusion
Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients

Locations

Country Name City State
China Guangdong General Hospital Guangzhou Guangdong
China Guangdong Province Traditional Chinese Medical Hospital Guangzhou Guangdong
China Guangdong Second Provincial General Hospital Guangzhou Guangdong
China Guangzhou Blood Center Guangzhou Guangdong
China Sun Yat-Sen University Cancer Center Guangzhou Guangdong
China The First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou Guangdong
China The First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong
China The Second Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong
China The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong
China ZhuJiang Hospital of Southern Medical University Guangzhou Guangdong

Sponsors (14)

Lead Sponsor Collaborator
Guangzhou Blood Center First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial Institute of Biological Products And Materia Medica, Guangdong Provincial People's Hospital, Guangdong Second Provincial General Hospital, Koo Foundation Sun Yat-Sen Cancer Center, Second Affiliated Hospital of Guangzhou Medical University, Shenzhen Second People's Hospital, Southern Medical University, China, Sun Yat-sen University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Third Affiliated Hospital, Sun Yat-Sen University, Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of Alloanti-D Immunization in Asian-type DEL Recipients Transfused With RhD+ RBCs For the Chinese Asian-type DEL recipients identified by the serological adsorption/elution test and HRM genotyping analysis, RhD+ RBC transfusion was performed. Then, the new blood samples from the patients were obtained after transfusion of RhD+ RBCs. The clinical significant alloantibodies against the common antigens of RBC were re-tested by antibody screening test. And the antibody screening test was performed using ID-DiaCell I-II-III Asia Kit (BIO-RAD, Cressier, Switzerland) in saline by the tube method and an indirect antiglobulin test (IAT) with the DG Gel Coombs card (Diagnostic Grifols, Barcelona, Spain). Meanwhile, RhCE and Asian- type DEL typing were also tested again. A median follow-up of 226 days (range, 32 to 1354 days) after RhD+ RBC transfusion
Secondary Adverse Transfusion Reaction Analysis in Asian-type DEL Recipients During or After RhD+ Blood Transfusion Matched D+ RBCs were provided to the 54 eligible Asian-type DEL patients by the Guangzhou Blood Center and transfused at their respective hospitals. Patients were monitored for any adverse events during transfusion and a few days thereafter, which mainly involved acute nor delayed hemolytic transfusion reactions, as well as nonhemolytic reactions, including allergic and febrile nonhemolytic reactions and circulatory overload during or after transfusion. If the symptoms of hemolysis were suspected, the laboratory biochemical measurements were also performed. During the blood transfusion and in the days of hospitalization
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Completed NCT01136590 - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery Phase 4
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00005303 - Effectiveness of AIDS Antibody Screening N/A
Completed NCT00005319 - Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine N/A
Completed NCT00005301 - Transfusion Safety Study (TSS) N/A
Completed NCT00000581 - Granulocyte Transfusion Study Phase 3
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Completed NCT02968654 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Enrolling by invitation NCT06019364 - Transfusion of Whole Blood in Acute Bleeding
Completed NCT04911413 - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery Phase 4
Recruiting NCT06102590 - Oxygen Extraction-guided Transfusion N/A
Completed NCT00400192 - Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury N/A
Completed NCT00000593 - Viral Activation Transfusion Study (VATS) N/A
Completed NCT05627544 - Blood Transfusion Applications in Hip Replacements
Completed NCT05581238 - Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.
Not yet recruiting NCT03429790 - Cell Salvage During Caesarean Section (CSCS) N/A
Completed NCT00822588 - Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not N/A
Withdrawn NCT00269971 - A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. Phase 3
Completed NCT03930355 - Perioperative Transfusion Related Outcome